Over the past two to three years there have been some small studies that have indicated that the use of concomitant anticoagulants along with docetaxel (chemotherapy) may improve overall survival The most recent examination of this issue was performed by a team led by Emmanuel S. Antonarakis, MD, of Johns Hopkins University in Baltimore. They [...]
Please take the ten minute anonymous survey about Life With Prostate Cancer. Go to: How We Live With Prostate Cancer Survey The direct link to the survey is: https://www.surveymonkey.com/s/livingwithprostatecancer The results will be used to let doctors and caregivers know the reality of our lives after treatment, as well as to understand survivorship differences between [...]
Abiraterone Acetate (Zytiga) and enzalutamide (Xtandi) are the newest generation hormonal agents. They both have demonstrated a survival advantage in men with castrate resistant prostate cancer (CRPC) who have already been treated with docetaxel (chemotherapy). Unfortunately all men who are responsive to both of these drugs eventually become resistant. Some men are subject to early [...]
Sometimes some of us just simply decide that we will not start any treatment or continue a treatment protocol simply because we don’t want to have treatment. This type of decision is different from our deciding that a specific treatment has too many side effects for the potential upside it might provide. Researchers set out [...]
Chemotherapy using docetaxel remains an important therapy, despite the newly approved drugs, to treat hormone refractory prostate cancer. Chemotherapy improves survival, however, all men taking it will eventually become refractory to the treatment. Zoledronic acid (ZA) is the most potent member of nitrogen-containing bisphosphonate family and has anti-tumor activity in prostate cancer. In a study, [...]